Cargando…

Deep and ongoing response of castrate-resistant prostate cancer on very low-dose enzalutamide in an elderly chemotherapy–naïve patient: a case report

BACKGROUND: Enzalutamide is an orally administered drug that blocks signaling in the androgen receptor with clinical activity in both chemotherapy–naive and post-chemotherapy patients with castrate-resistant prostate cancer (CRPC). Enzalutamide is generally well-tolerated, but dose reductions are no...

Descripción completa

Detalles Bibliográficos
Autores principales: Boerrigter, Emmy, Havenith, Thomas, van Erp, Nielka P., Schnog, John-John B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149336/
https://www.ncbi.nlm.nih.gov/pubmed/33817752
http://dx.doi.org/10.1007/s00280-021-04269-3
_version_ 1783697939721355264
author Boerrigter, Emmy
Havenith, Thomas
van Erp, Nielka P.
Schnog, John-John B.
author_facet Boerrigter, Emmy
Havenith, Thomas
van Erp, Nielka P.
Schnog, John-John B.
author_sort Boerrigter, Emmy
collection PubMed
description BACKGROUND: Enzalutamide is an orally administered drug that blocks signaling in the androgen receptor with clinical activity in both chemotherapy–naive and post-chemotherapy patients with castrate-resistant prostate cancer (CRPC). Enzalutamide is generally well-tolerated, but dose reductions are nonetheless needed in case of side effects. CASE: An 82-year-old patient with chemotherapy–naive metastatic castration-resistant prostate cancer was treated with a very low dose of 40 mg enzalutamide once daily. The trough levels of enzalutamide and the active metabolite N-desmethylenzalutamide were 4.5 mg/L and 3.0 mg/L, respectively. This exposure provided a long-term response without any significant side effects. CONCLUSION: Low doses of enzalutamide may be efficacious, while also reducing the risk of side effects. Furthermore, employing a lower dose would reduce healthcare costs and increase access to enzalutamide. Studies exploring the efficacy of lower enzalutamide doses are warranted.
format Online
Article
Text
id pubmed-8149336
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-81493362021-06-01 Deep and ongoing response of castrate-resistant prostate cancer on very low-dose enzalutamide in an elderly chemotherapy–naïve patient: a case report Boerrigter, Emmy Havenith, Thomas van Erp, Nielka P. Schnog, John-John B. Cancer Chemother Pharmacol Short Communication BACKGROUND: Enzalutamide is an orally administered drug that blocks signaling in the androgen receptor with clinical activity in both chemotherapy–naive and post-chemotherapy patients with castrate-resistant prostate cancer (CRPC). Enzalutamide is generally well-tolerated, but dose reductions are nonetheless needed in case of side effects. CASE: An 82-year-old patient with chemotherapy–naive metastatic castration-resistant prostate cancer was treated with a very low dose of 40 mg enzalutamide once daily. The trough levels of enzalutamide and the active metabolite N-desmethylenzalutamide were 4.5 mg/L and 3.0 mg/L, respectively. This exposure provided a long-term response without any significant side effects. CONCLUSION: Low doses of enzalutamide may be efficacious, while also reducing the risk of side effects. Furthermore, employing a lower dose would reduce healthcare costs and increase access to enzalutamide. Studies exploring the efficacy of lower enzalutamide doses are warranted. Springer Berlin Heidelberg 2021-04-04 2021 /pmc/articles/PMC8149336/ /pubmed/33817752 http://dx.doi.org/10.1007/s00280-021-04269-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Short Communication
Boerrigter, Emmy
Havenith, Thomas
van Erp, Nielka P.
Schnog, John-John B.
Deep and ongoing response of castrate-resistant prostate cancer on very low-dose enzalutamide in an elderly chemotherapy–naïve patient: a case report
title Deep and ongoing response of castrate-resistant prostate cancer on very low-dose enzalutamide in an elderly chemotherapy–naïve patient: a case report
title_full Deep and ongoing response of castrate-resistant prostate cancer on very low-dose enzalutamide in an elderly chemotherapy–naïve patient: a case report
title_fullStr Deep and ongoing response of castrate-resistant prostate cancer on very low-dose enzalutamide in an elderly chemotherapy–naïve patient: a case report
title_full_unstemmed Deep and ongoing response of castrate-resistant prostate cancer on very low-dose enzalutamide in an elderly chemotherapy–naïve patient: a case report
title_short Deep and ongoing response of castrate-resistant prostate cancer on very low-dose enzalutamide in an elderly chemotherapy–naïve patient: a case report
title_sort deep and ongoing response of castrate-resistant prostate cancer on very low-dose enzalutamide in an elderly chemotherapy–naïve patient: a case report
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149336/
https://www.ncbi.nlm.nih.gov/pubmed/33817752
http://dx.doi.org/10.1007/s00280-021-04269-3
work_keys_str_mv AT boerrigteremmy deepandongoingresponseofcastrateresistantprostatecanceronverylowdoseenzalutamideinanelderlychemotherapynaivepatientacasereport
AT haveniththomas deepandongoingresponseofcastrateresistantprostatecanceronverylowdoseenzalutamideinanelderlychemotherapynaivepatientacasereport
AT vanerpnielkap deepandongoingresponseofcastrateresistantprostatecanceronverylowdoseenzalutamideinanelderlychemotherapynaivepatientacasereport
AT schnogjohnjohnb deepandongoingresponseofcastrateresistantprostatecanceronverylowdoseenzalutamideinanelderlychemotherapynaivepatientacasereport